Back

Antithrombotic therapy in patients with takotsubo cardiomyopathy: is heparin associated with lower mortality? - a nationwide cohort analysis

1 September 2025 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Post-myocardial infarction management Anticoagulants ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Sadahiro Hijikata

Tokyo Medical And Dental University - Science Tokyo, Tokyo (Japan)

5 More presentations in this session

Presentation thumbnail
Beta-blockers improved cardiovascular outcome in AMI patients with severe heart failure: a multi-center real-world study
Doctor R. Guo (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Beta-blocker duration and long-term cardiovascular risk after myocardial infarction with reduced ejection fraction
Doctor S. Fang (Bristol, GB)
Abstract Slides Video
Presentation thumbnail
Proton pump inhibitors in myocardial infarction: safety paradox in Type 1 vs. Type 2---a multicenter retrospective cohort study
Doctor J. Ren (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
Relationship between baseline LDL cholesterol levels and cardiovascular outcomes in adults with cardiovascular disease and overweight or obesity: an exploratory analysis of the SELECT trial
Professor M. Shechter (Ramat Gan, IL)
Abstract Slides Video
Presentation thumbnail
Effect of oral semaglutide on CV outcomes across the vascular disease spectrum, from no vascular disease to polyvascular disease, in high-risk type 2 diabetes
Associate Professor M. Cavender (Chapel Hill, US)
Abstract Slides

Access the full session

Session thumbnail
Post-myocardial infarction management

The Event

Event poster

ESC Congress 2025

1 September 2025 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Clinical outcomes of edoxaban treatment without parenteral anticoagulation therapy for acute venous thromboembolism: Insight from the COMMAND VTE Registry-2
thumbnail
Congress Presentation
Post-PCI anticoagulation with unfractionated heparin in acute coronary syndrome: insight from the STOPDAPT-3 trial
thumbnail
Congress Presentation
Cardiovascular and non-cardiovascular prescribing and mortality after takotsubo

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources